July 11, 2022
The new article "Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis" by Galina Kolesova, Alexander Stepanov, Galina Lebedeva and Oleg Demin has been published in Journal of Pharmacokinetics and Pharmacodynamics.
Galina Kolesova comments on the article, "The traditional approach of QSP modeling includes fitting a model output to a series of mean data values. As a result, the parameters of the model represent fixed numbers enabling the description of mean data, thus we generated the so-called “reference patient”. However, the results of clinical trials include a description of variability in patients’ responses to a drug, which is typically expressed in terms of conventional statistical parameters such as standard deviations (SDs) from mean values. To allow a QSP model to reproduce the variability observed in response to a drug administration, a virtual patient (VP) population is usually generated and applied. In our study, we propose and compare four different approaches to generate virtual patient populations based on experimentally measured mean data and statistics, namely, (1) Monte Carlo Markov chain (MCMC), (2) model fitting to Monte Carlo samples, (3) population of clones, and (4) stochastically bounded selection. We applied these approaches to generate virtual patient populations in the QSP model of erythropoiesis. Our main task was to create a sample of virtual patients of the same size as that in clinical trials".
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Edinburgh, UK (INSYSBIO UK LIMITED), Moscow, Russia (INSYSBIO LLC) and Cyprus (INSYSBIO CY Ltd). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | March 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
1.
09 Mar 2017 14:10
ISBM Enclosed Conference was held
20-22 February 2017 the 10th ISBM Enclosed Conference was held. For ten years the employees annually have been meeting together to share their scientific results and talk over future plans. ISBM did a great job in this working year.
|
10
|
11
|
12
|
|
13
|
14
|
15
1.
15 Mar 2017 11:49
Institute for Systems Biology participates in American Society for Clinical Pharmacology and Therapeutics 2017 Meeting
Institute for Systems Biology Moscow – a company, providing modeling services for innovative drug design, announced participation in ASCPT 2017 Meeting, which is held on 15-18 March in Washington, DC. ISBM will present several studies and demonstrate an updated version of platform for quantitative systems pharmacology modeling of immune response - Immune Response Template (IRT).
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
1.
28 Mar 2017 17:56
Not all therapies are effective: Institute for Systems Biology Moscow to present the results of the Alzheimer’s disease Systems Pharmacology Modeling
Moscow, Russia – March 28, 2017. On the 1st April, Tatyana Karelina, ISBM leading specialist in neurodegenerative field, will present a poster entitled "Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model" at the 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders to be held on March 29 - April 2, Vienna, Austria.
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
